Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ruling to FDA in Nutraceutical case

This article was originally published in The Tan Sheet

Executive Summary

U.S. District Judge for the district of Utah, Paul G. Cassell finds FDA's rulemaking banning ephedra dietary supplements was "procedurally and substantially proper" on March 16. However, Jonathan W. Emord of Emord & Associates says in an e-mail "one critical point" in the decision "cuts against the FDA": Cassell found FDA "explicitly limited its rulemaking and the reach of its final rule" to ephedra supplements. Thus, even if this decision stands it ensures the Final Rule "is not precedent for the creation of a supplement-wide risk-benefit adulteration standard," Emord says. Nutraceutical had sought summary judgment that the agency acted in an arbitrary and capricious manner and violated administrative procedure law in issuing the 2004 ban of ephedrine-alkaloid dietary supplements (1"The Tan Sheet" Feb. 19, 2007, p. 13). Emord says the law firm will file a notice of appeal to the Tenth Circuit on March 19...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS100318

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel